HCW Biologics extends $7M license fee payment from WY Biotech to Sept 30, 2025

HCW Biologics Inc.

WY Biotech completed due diligence and elected to continue exclusive license agreement with HCW Biologics.
WY Biotech's obligation includes a $7.0 million upfront license fee, originally due earlier.
Parties agreed to extend payment deadline; confirmation of wire transfer expected on or before Sept 30, 2025.
Amendment accommodates WY Biotech's timing for finalizing CDMO and investor agreements.

item 1.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.